Kate Dinneen

Dr. Kate Dinneen

Trinity College Dublin
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Histopathology
Verified
Journal Article
Open access
RARicardo Almeida‐Magana
Ricardo Almeida‐Magana
MAMatthew Au
Matthew Au
TATarek Al‐Hammouri
Tarek Al‐Hammouri
MMManju Mathew
Manju Mathew
KDKate Dinneen
Kate Dinneen
AHAiman Haider
Aiman Haider
Introduction and objectives: Fluorescence confocal microscopy (FCM) is a new imaging modality capable of generating digital microscopic resolution scans of fresh surgical specimens, and holds potential as an alternative to frozen section (FS) analysis for intra‐operative assessment of surgical margins. Previously, we described the LaserSAFE technique as an application of FCM for margin assessment in robot‐assisted radical prostatectomy (RARP) using the Histolog® scanner. This study describes the accuracy and inter‐rater agreement of FCM imaging compared to corresponding paraffin‐embedded analysis (PA) among four blinded pathologists for the presence of positive surgical margins (PSM).Materials and methods: RARP specimens from patients enrolled in the control arm of the NeuroSAFE PROOF study (NCT03317990) were analysed from April 2022 to February 2023. Prostate specimens were imaged using the Histolog® scanner before formalin fixation and PA. Four trained assessors, blinded to PA, reviewed and analysed FCM images of the posterolateral prostatic surface.Results: A total of 31 prostate specimens were included in the study. PA per lateral side of the prostate identified 11 instances of positive margins. Among the four histopathologists included in our study, FCM achieved a sensitivity of 73–91 and specificity of 94–100% for the presence of PSM. Fleiss’ Kappa for inter‐rater agreement on PSM was 0.78 (95% confidence interval = 0.64–0.92), indicating substantial agreement.Conclusion: This blinded analysis of FCM versus PA among histopathologists with different experience levels demonstrated high accuracy and substantial inter‐rater agreement for diagnosing PSM. This supports the role of the FCM as an alternative to FS.

13 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
NDNoel Donlon
Noel Donlon
ASAndrew Sheppard
Andrew Sheppard
MDmaria davern
maria davern
FOFiona O’Connell
Fiona O’Connell
JPJames Phelan
James Phelan
MDMargaret Dunne
Margaret Dunne
Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor prognosis and incidence is increasing rapidly in the Western world. Multi-modal treatment has improved survival outcomes but only for a minority of patients. Currently no markers have been identified to predict treatment response. This study investigated the association between clinical outcomes and pre-treatment levels of 54 serum proteins in n = 80 patients with EAC. Low tumor regression grade (TRG), corresponding to a favorable treatment response, was linked to prolonged overall survival (OS). CCL4 was higher in patients with a favorable treatment response, while Tie2 and CRP were higher in poor responders. Elevated CCL22 and CCL26 was associated with improved OS, while elevated IL-10 showed a negative association. CCL3, CCL4, IL-1α and IL-12/IL23p40 were highest in individuals with no adverse features of tumor biology, whereas levels of Tie2 and VEGF were lowest in this cohort. CCL4 was also elevated in patients with high tumor lymphocyte infiltration. Comparison of matched pre- and post-treatment serum (n = 28) showed a large reduction in VEGFC, and a concomitant increase in other cytokines, including CCL4. These data link several serum markers with clinical outcomes, highlighting an important role for immune cell trafficking in the EAC antitumor immune response.

5 September 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JNJames Nolan
James Nolan
CMCatherine Murphy
Catherine Murphy
KDKate Dinneen
Kate Dinneen
GLGreg Lee
Greg Lee
EHElizabeth Higgins
Elizabeth Higgins
EVElisabeth Vandenberghe
Elisabeth Vandenberghe
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma (B-NHL) with a number of clinically relevant pathological subtypes including ‘indolent’, classical, blastoid and pleomorphic, associated ...

8 February 2021 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
KDKate Dinneen
Kate Dinneen
ABAnne-Marie Baird
Anne-Marie Baird
CRCiara Ryan
Ciara Ryan
OSOrla Sheils
Orla Sheils
Gastroesophageal junction adenocarcinomas (GEJA) have dramatically increased in incidence in the western world since the mid-20th century. Their prognosis is poor, and conventional anti-cancer therapies do not significantly improve survival outcomes. These tumours are comprised of a heterogenous population of both cancer stem cells (CSC) and non-CSCs, with the former playing a crucial role in tumorigenesis, metastasis and importantly drug resistance. Due to the ability of CSCs to self-replicate indefinitely, their resistance to anti-cancer therapies poses a significant barrier to effective treatment of GEJA. Ongoing drug development programmes aim to target and eradicate CSCs, however their characterisation and thus identification is difficult. CSC regulation is complex, involving an array of signalling pathways, which are in turn influenced by a number of entities including epithelial mesenchymal transition (EMT), microRNAs (miRNAs), the tumour microenvironment and epigenetic modifications. Identification of CSCs commonly relies on the expression of specific cell surface markers, yet these markers vary between different malignancies and indeed are often co-expressed in non-neoplastic tissues. Development of targeted drug therapies against CSCs thus requires an understanding of disease-specific CSC markers and regulatory mechanisms. This review details the current knowledge regarding CSCs in GEJA, with particular emphasis on their role in drug resistance.

17 July 2020 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
KDKate Dinneen
Kate Dinneen
DTDeirdre Mary Timlin
Deirdre Mary Timlin
KOKevin O'HAre
Kevin O'HAre
JWJan Walker
Jan Walker
GCGiuseppa Castriciano
Giuseppa Castriciano
RFRichard Flavin
Richard Flavin

25 March 2019 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
KDKate Dinneen
Kate Dinneen
CRCiara Ryan
Ciara Ryan
CGCliona Grant
Cliona Grant
BDBarbara Dunne
Barbara Dunne
LBLarry Bacon
Larry Bacon
RFRichard Flavin
Richard Flavin
Lymphoma diagnosis is complex, requiring a wide array of adjunctive tests to reach accurate diagnoses. We retrospectively examined the rates of concordance between referral and review lymphoma diagnoses on cases referred to St James’s Hospital, Dublin for multidisciplinary team review between 2013 and 2016. Frequency and cost of adjunctive diagnostic tests performed were also analysed. The overall discordance rate was 7.8% (14/179), compared with rates of 6%–48% in the published literature. 13 discordant cases required a change in clinical management following review of the referred diagnosis. Of all referred cases, 33.5% (60/179) required extra analyses to reach a final diagnosis, costing the reference laboratory €35463.40. We conclude that establishment of centralised haematopathology diagnostic networks would help reduce the rate of revision made to lymphoma diagnoses by providing specialist haematopathologist input and access to ancillary testing.